Thomas William LeBlanc, MD

Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member of the Duke Cancer Institute
Campus mail 2424 Erwin Road, Suite 602, Durham, NC 27705
Phone (919) 668-2115
Email address thomas.leblanc@duke.edu

Dr. LeBlanc is a medical oncologist, palliative care physician, and patient experience researcher.  His clinical practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions and acute leukemias including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs, CML).  He is an active member of the inpatient non-transplant hematologic malignancies care team, based on the 9100 ward of Duke University Hospital.

His research interests converge on common issues faced by people with cancer, particularly those with high-risk or relapsed/refractory hematologic malignancies. Issues of symptom burden and quality of life are of central importance in these settings, and may lead patients to face difficult decision-making scenarios. Dr. LeBlanc’s research explores the experience of patients and families in these settings, and aims to improve patients experiences living with blood cancers, including the involvement of specialist palliative care services to provide an extra layer of support along with their comprehensive cancer care, to improve symptom management and quality of life.

Dr. LeBlanc is the recipient of a Junior Career Development Award grant from the National Palliative Care Research Center (NPCRC), a Sojourns Scholars Leadership Award from the Cambia Health Foundation, and a Mentored Research Scholar Grant from the American Cancer Society. These grants have funded efforts to better understand the experience of patients living with AML, including studies of symptom burden, quality of life, distress, understanding of prognosis, and treatment decision-making. This work has been mentored by a team of expert researchers, including Drs. Amy Abernethy, James Tulsky, Karen Steinhauser, Kathryn Pollak, and Peter Ubel.  Dr. LeBlanc's work in palliative care research led to his recognition as an "Inspirational Leader under 40" by the American Academy of Hospice and Palliative Medicine (AAHPM), and "fellow" status from the Academy in 2016. Dr. LeBlanc was the 2017-18 Chair of the ASCO Ethics Committee, and Chairs the Scientific Review Committee of the NIH/NINR-funded Palliative Care Research Cooperative Group (PCRC; www.palliativecareresearch.org). He has served on various national guideline panels for AML, and for palliative/supportive care issues in oncology. 

He completed residency training in Internal Medicine at Duke, as well as fellowships in Medical Oncology and Hospice and Palliative Medicine.  He graduated from the Duke University School of Medicine, also earning a Master of Arts degree in Philosophy during that time, and served as Chief Medical Resident at the Durham VA Medical Center in 2010-11.  He holds board certifications in Medical Oncology, and in Hospice and Palliative Medicine.  He is actively involved with teaching of medical students and housestaff at Duke, particularly with regards to issues of patient-doctor communication, and is mentoring several Duke trainees on research projects.

Education and Training

  • Fellow, Medical Oncology, Duke University School of Medicine, 2012 - 2013
  • Fellowship, Hospice And Palliative Medicine, Duke University School of Medicine, 2011 - 2012
  • Chief Medical Resident, Duke University School of Medicine, 2010 - 2011
  • Resident, Duke University School of Medicine, 2007 - 2009
  • Intern, Duke University School of Medicine, 2006 - 2007
  • M.D., Duke University, 2006

Publications

Salinger, Maggie R., Nathan A. Boucher, Thomas W. LeBlanc, Kevin C. Oeffinger, Kathryn Pollak, Jesse D. Troy, and Arif H. Kamal. “Why palliative care is the answer to the serious illness question in payment reform.” Am J Manag Care 26, no. 4 Spec No. (April 2020): SP127–28. https://doi.org/10.37765/ajmc.2020.42967.

PMID
32286037
Full Text

El-Jawahri, Areej, Ashley M. Nelson, Tamryn F. Gray, Stephanie J. Lee, and Thomas W. LeBlanc. “Palliative and End-of-Life Care for Patients With Hematologic Malignancies.” J Clin Oncol 38, no. 9 (March 20, 2020): 944–53. https://doi.org/10.1200/JCO.18.02386.

PMID
32023164
Full Text

Loh, Kah Poh, Huiwen Xu, Anthony Back, Paul R. Duberstein, Supriya Gupta Mohile, Ronald Epstein, Colin McHugh, et al. “Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study.” Cancer 126, no. 6 (March 15, 2020): 1306–14. https://doi.org/10.1002/cncr.32656.

PMID
31809566
Full Text

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol, March 12, 2020. https://doi.org/10.1002/ajh.25781.

PMID
32162718
Full Text

Robles, Joanna M., Jesse D. Troy, Kristin M. Schroeder, Paul L. Martin, and Thomas W. LeBlanc. “The Effect of Limited-English Proficiency on Hematopoietic Stem Cell Transplantation Outcomes: A Retrospective Cohort Study of Hispanic Pediatric Transplant Patients at a Single Institution.” In Biology of Blood and Marrow Transplantation, 26:S195–96. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Wilson, Jennifer G., Diana P. English, Clark G. Owyang, Erica A. Chimelski, Corita R. Grudzen, Hong-Nei Wong, Rebecca A. Aslakson, and Rebecca A. AAHPM Research Committee Writing Group. “End-of-Life Care, Palliative Care Consultation, and Palliative Care Referral in the Emergency Department: A Systematic Review.” J Pain Symptom Manage 59, no. 2 (February 2020): 372-383.e1. https://doi.org/10.1016/j.jpainsymman.2019.09.020.

PMID
31586580
Full Text

Navari, Rudolph M., Kathryn J. Ruddy, Thomas W. LeBlanc, Rebecca Clark-Snow, Rita J. Wickham, Gary Binder, Tammy Coberly, Ravi Potluri, Luke M. Schmerold, and Eric J. Roeland. “Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care.” Jco Oncol Pract 16, no. 2 (February 2020): e132–38. https://doi.org/10.1200/JOP.19.00457.

PMID
31800352
Full Text

Yuen, Eva Y. N., Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Thomas W. LeBlanc, Kathryn Hamilton, and Kevin Stein. “Unintentional weight loss, its associated burden, and perceived weight status in people with cancer.” Support Care Cancer 28, no. 1 (January 2020): 329–39. https://doi.org/10.1007/s00520-019-04797-y.

PMID
31049669
Full Text

LeBlanc, Matthew R., Rachel Hirschey, Ashley Leak Bryant, Thomas W. LeBlanc, and Sophia K. Smith. “How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review.” Qual Life Res, December 17, 2019. https://doi.org/10.1007/s11136-019-02392-6.

PMID
31848847
Full Text

Pages